Nexalin - Pangali EV/EBITDA NXL

Nexalin Technology, Inc. (NXL) develops neurostimulation equipment to treat migraines and anxiety disorders, leveraging regulatory approvals and the expansion of its clinic network. The company's price chart with the 0.00 indicator links these achievements to the development of non-invasive systems for combating insomnia in the B2C segment. The business remains crisis-resilient, as its growth depends on trial results and the launch of new products into the market.

This indicator determines business value accounting for net debt relative to operating profit, measuring the payback period of assets and their resilience to financial shocks. The EV/EBITDA trend for Nexalin Technology, Inc. (NXL) reflects the risks of slow neurostimulation adoption in clinical practice, where high chart volatility signals instability in the asset's fundamental valuation.